JMP $CYCC "potential ann. of registration-dir. program in res. MDS could be astore of incremental upside" -
While sapacitabine’s prospects in AML within SEAMLESS have recently been quelled
after failing to pass muster during an interim futility analysis, the decision by the data monitoring board
to continue the trial suggests that there is still the probability for a positive read out, albeit a low
probability. The potential announcement of a registration-directed program in resistant MDS could be a
store of incremental upside, in our view

Reply · Report Post